NECTIN4 and neoplasm: Focusing on enfortumab vedotin (EV), an FDA-approved ADC targeting nectin-4 (11), we sought to explore whether PET imaging measures of target engagement at the tumor, an early biomarker of drug-target interaction, could lead to more precise understanding of dose-exposure-response relationships.